异时性原发性肺癌的一种新策略：立体定向体部放疗联合同步化疗。
A new strategy for metachronous primary lung cancer: stereotactic body radiation therapy with concurrent chemotherapy.
作者信息
Takeshita Jumpei, Masago Katsuhiro, Kato Ryoji, Otsuka Kyoko, Okuda Chiyuki, Hata Akito, Kaji Reiko, Fujita Shiro, Takayama Kenji, Kokubo Masaki, Katakami Nobuyuki
机构信息
Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan
Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
出版信息
Anticancer Res. 2015 May;35(5):3103-7.
BACKGROUND/AIM: Patients with malignant lung cancer often develop a solitary pulmonary nodule after treatment of the initial cancer. In those cases, it is difficult to distinguish primary lung cancer (PLC) from lung metastasis. Therefore, both local therapy for a single lung lesions and systemic therapy for micrometastases are needed. This retrospective study aimed to evaluate the safety and tolerability of concurrent stereotactic body radiation therapy (SBRT) and chemotherapy in patients with metachronous PLC.
PATIENTS AND METHODS
We reviewed the records of 10 patients with metachronous PLC treated with SBRT and concurrent chemotherapy with curative intent from 2007 to 2013. The delivered radiation dose was 48 Gy in four fractions.
RESULTS
All patients received SBRT with concurrent chemotherapy on schedule. Complete response rate was 90%. Safety profile of this treatment was compatible with that of traditional chemoradiotherapy.
CONCLUSION
Our study showed good feasibility and safety for SBRT with concurrent chemoradiotherapy.
背景/目的：恶性肺癌患者在初始癌症治疗后常出现孤立性肺结节。在这些病例中，很难区分原发性肺癌（PLC）和肺转移瘤。因此，对于单个肺部病变既需要局部治疗，对于微转移又需要全身治疗。这项回顾性研究旨在评估同步立体定向体部放疗（SBRT）和化疗在异时性PLC患者中的安全性和耐受性。
患者与方法
我们回顾了2007年至2013年期间10例接受SBRT和同步化疗以达到治愈目的的异时性PLC患者的记录。给予的放射剂量为48 Gy，分4次给予。
结果
所有患者均按计划接受了SBRT和同步化疗。完全缓解率为90%。该治疗的安全性与传统放化疗相当。
结论
我们的研究表明SBRT同步放化疗具有良好的可行性和安全性。
Zotero 插件